Boundless Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$2.53next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly92.8MTarget: Sufficient to fund operations into the second half of 2028
KOMODO-1 Clinical Trial Enrollment QuarterlyTarget: Complete enrollment and deliver initial safety, PK/PD, and efficacy proof-of-concept data
Watch Items
- BBI-940 Clinical Safety and EfficacyTrigger: Initial proof-of-concept clinical data readout from the KOMODO-1 trialAction: Evaluate therapeutic index, safety profile, and signs of tumor regression in ecDNA+ breast cancer patients to determine late-stage development strategy.
- ECHO Diagnostic Software ValidationTrigger: Clinical trial enrichment success rate using ECHO algorithmAction: Assess the accuracy of the ECHO algorithm in identifying ecDNA-bearing tumors from routine NGS data to ensure proper patient selection.
Research as of 20 Jun 2026